Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: continuously (64)

Nivolumab ver 1 (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indicati
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf

Nivolumab 240mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab (240mg-14 days) Regimen • NSCLC – Nivolumab (240mg-14days) Indication • Nivolumab monotherapy
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-240mg.pdf

Pembrolizumab_400mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (400mg) Regimen • Lung Cancer – Pembrolizumab (400mg) Indication The treatment of untreated PD-L1 positive metastat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (NSCLC)

Description: Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The treatment of untreated PD-L1 positive metastat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg)
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

Vinblastine Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA VINBLASTINE Regimen Lymphoma – Vinblastine Indication Non-Hodgkin’s Lymphoma Hodgkin’s Lymphoma Toxicity
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Vinblastine-Ver-1.1.pdf

Rituximab (weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (weekly) Regimen Lymphoma – Rituximab (weekly) Indication CD20 positive indolent non Hodgkin’s
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-weekly.pdf

Rituximab (3 weekly)

Description: Chemotherapy Protocol LYMPHOMA RITUXIMAB (3 Weekly) Regimen Lymphoma – Rituximab (3 weekly) Indication Non Hodgkin’s Lymphoma in combin
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-3-weekly.pdf

Prednisolone – Vincristine (Pre phase) Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA PREDNISOLONE - VINCRISTINE (Pre phase) Regimen Lymphoma – Prednisolone-Vincristine (Pre phas
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Prednisolone-–-Vincristine-Pre-phase-Ver-1.1.pdf

Nivolumab (lymphoma)

Description: Chemotherapy Protocol LYMPHOMA Nivolumab Regimen • Lymphoma – Nivolumab Indication • Nivolumab is recommended as an option for treating r
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Nivolumab.pdf

301 to 310 of 733

Previous … 29 30 31 32 33 … Next